ArticleFrontiers in immunology2025
Case Report: Unexpected non-pathogenic autoantibodies without clinical involvement following PD-L1 blockade.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several immune checkpoint inhibitors (ICIs) have improved outcomes in extensive-stage small cell lung cancer (ES-SCLC), but immune-related adverse events (irAEs) remain a concern. Beyond irAEs, ICIs may induce various immune changes requiring further investigation. A 74-year-old man with ES-SCLC received atezolizumab plus chemotherapy and developed aspiration pneumonia due to dysphagia. Concurrently, elevated anti-glomerular basement membrane, antinuclear, double-stranded DNA, myeloperoxidase-antineutrophil cytoplasmic, proteinase 3 antibodies were detected without any clinical involvement. Moderate glucocorticoids were administered, and during a 3-month follow-up, he remained entirely asymptomatic, with persistently high antibody titers. The case report presents specific autoantibodies following PD-L1 blockage and questions their pathogenic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.